FIG 1.
Summary of treatment response at week 96 by treatment group. The percentage of patients for either the TAF (left) or TDF (right) treatment group is depicted for each outcome through week 96. Patients that missed their week 96 visit but had suppressed HBV DNA at the previous visit were included in the <69-IU/ml group. Virologic breakthrough was defined as a confirmed HBV DNA level of ≥69 IU/ml after having <69 IU/ml or a ≥1.0-log10 increase in HBV DNA from nadir. Patients with one visit that met these criteria were classified as viremic in the absence of viral breakthrough.